<DOC>
	<DOCNO>NCT01934790</DOCNO>
	<brief_summary>Eligible subject must complete 6 dos treatment radium-223 dichloride experience radium-223 dichloride-related SAEs ( serious adverse event ) CTCAE ( Common Terminology Criteria Adverse Events ) Grade 3 4 adverse event initial course radium-223 dichloride lead discontinuation treatment . 40 Subjects enrol receive 6 dos radium-223 dichloride 50 kBq/kg IV every 4 week . The subject evaluate AEs ( adverse event ) laboratory test visit every 4 week , prior receive radium-223 dichloride . After end treatment visit subject enter active follow period . Related AEs SAEs Lab test evaluate visit every 4 week first 12 week , every 12 week 2 year last dose radium-223 dichloride . After 2 year active follow-up , subject enter long-term follow-up period follow via telephone follow-up 6-month interval late toxicity survival 7 year last dose radium-223 dichloride death . Joint safety review regularly take place oversee safety subject conduct regular interval . An interim analysis safety data conduct study .</brief_summary>
	<brief_title>Re-treatment Safety Radium-223 Dichloride Castration-resistant Prostate Cancer With Bone Metastases</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Succinylcholine</mesh_term>
	<mesh_term>Radium Ra 223 dichloride</mesh_term>
	<criteria>Histologically cytologically confirm adenocarcinoma prostate give point time disease history CRPC ( castrationresistant prostate cancer ) clinical radiologically confirm bone progression Treatment 6 injection radium223 dichloride 50 kBq/kg evidence progression bone ( accord Prostate Cancer Clinical Trials Working Group 2 [ PCWG2 ] criterion ) first course treatment Signed write informed consent prior participate study related procedure . Willing able comply protocol , include followup visit examination History radium223 dichloriderelated serious adverse event ( SAE ) CTCAE Grade 3 4 adverse event ( AE ) initial course radium223 dichloride treatment lead discontinuation treatment Less 30 day last dose administer initial course radium223 dichloride treatment Visceral metastases 1 cm great large diameter / require local systemic therapeutic intervention , assess abdominal pelvic magnetic resonance imaging ( MRI ) / compute tomography ( CT ) scan / chest Xray within 30 day start treatment Lymphadenopathy lymph node exceed 6 cm shortaxis diameter / require local systemic therapeutic intervention . Enlarged lymph node size lymphadenopathy think contributor concurrent hydronephrosis . Current central nervous system ( CNS ) metastases Chronic condition associate nonmalignant abnormal bone growth ( e.g. , confirm Paget 's disease bone ) Treatment chemotherapy initial course radium223 dichloride treatment Prior hemibody external radiotherapy Prior systemic radiotherapy strontium89 , samarium153 , rhenium186 , rhenium188 Any serious illness medical condition Crohn 's disease ulcerative colitis History document bone marrow dysplasia Unmanageable fecal incontinence Imminent establish spinal cord compression base clinical finding / MRI yet treat Other malignancy treat within last 3 year ( except nonmelanoma skin cancer lowgrade superficial bladder cancer )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>